Novartis (NVS) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 01/31/24
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readoutsGlobeNewsWire • 01/31/24
Novartis (NVS) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • 01/26/24
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumorsGlobeNewsWire • 01/19/24
Novartis (NVS) Stock Slides as Market Rises: Facts to Know Before You TradeZacks Investment Research • 01/19/24
Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024Zacks Investment Research • 01/18/24
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record HighZacks Investment Research • 01/16/24
Novartis (NVS) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 01/13/24
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must WatchSeeking Alpha • 01/10/24
Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout DealInvestors Business Daily • 01/08/24